How the New 5-Year SYFOVRE Data May Impact GA Treatment
Sit down with Drs. Singh and Dhoot as they review 5-year GALE trial data on SYFOVRE (pegcetacoplan) for the treatment of geographic atrophy (GA).
New Content
Evidence Based Retina
Recently Published
PHARMACEUTICALS
Revolutionizing Retina Treatments to Preserve Sight
Join Drs. Singh and Quezada-Ruiz as they discuss advancements in treating Stargardt disease and other retinal conditions with oral gildeuretinol.
Rishi P. Singh, MD, FASRS, Carlos Quezada-Ruiz, MD, FASRSJune 11, 2026
PHARMACEUTICALS
IZERVAY Produces Positive Results in GATHER1 and GATHER2 Studies
Join Drs. Singh and Chang to review recent findings from a post-hoc analysis of the GATHER studies on functional outcomes in patients receiving IZERVAY.
Rishi P. Singh, MD, FASRS, Margaret A. Chang, MD, MSMay 28, 2026
PRODUCTS & TECHNOLOGY
A Cost-Analysis of Secondary IOLs and Pars Plana Vitrectomy
Join Drs. Singh and Meshkin as they discuss findings from a recent cost-analysis retrospective study of reimbursement rates for secondary IOL surgery.
Rishi P. Singh, MD, FASRS, Ryan Sameen Meshkin, MDMay 25, 2026
CASE REPORTS
Uveal Effusion Syndrome: A Case Report from Caroline Awh, MD
Rishi P. Singh, MD, FASRS, Caroline Awh, MDApril 21, 2026